FPIs pour Rs 15,800 crore into pharma since July

Foreign portfolio investors invested ₹15,800 crore into Indian pharmaceutical shares between July and the first half of September. Despite this sector-wide inflow, IPCA Laboratories Limited

, Laurus Labs Limited (LAURUSLABS), and Glenmark Pharmaceuticals Limited (GLENMARK) were the top losers in the Nifty Pharma index on September 25. A ₹15,800 crore inflow over roughly two and a half months represents a substantial, sustained allocation into one sector, not a single day's rotation. Yet on the same day this figure was reported, three specific pharma names sat at the bottom of the sector index, moving opposite to the direction the aggregate flow data would suggest. Aggregate buying and individual stock performance can diverge sharply, even within the same sector and the same time window. Sector-wide FPI inflow data tells you capital is broadly rotating into pharma as a theme, but it says nothing about which specific companies within that sector are receiving that capital versus which ones are being sold even as the sector aggregate rises. IPCA Laboratories, Laurus Labs, and Glenmark Pharmaceuticals underperforming on the same day this inflow figure was published means either the money is concentrated in a narrower set of pharma names, or these three carry company-specific concerns strong enough to offset the sector tailwind. I would want to see the actual FII shareholding change for these three specific companies before assuming the sector inflow number applies evenly. A single sector-level statistic can mask real dispersion underneath it, exactly the kind of gap worth checking rather than assuming. My stance: the sector-level inflow is real, but I am not extending that as a positive read to these three specific names without their own company-level flow data. Watching individual shareholding disclosures for IPCA Laboratories, Laurus Labs, and Glenmark Pharmaceuticals before forming a view on any of them.